Treatment Effect
death
Evaluation of the weekly odds of the primary outcome by treatment yielded similar results to the primary results from the INVESTED trial. High-dose was not superior to standard-dose vaccine in its association with risk of the primary outcome (CP hospitalization or death) in the prespecified primary analysis after adjusting for state (OR, 1.07; 95% CI, 0.95-1.20; 